NCT00225121 - Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

October 11, 2005

Primary Completion Date

April 3, 2007

Study Completion Date

September 23, 2010

Conditions

Neoplasms

Interventions

DRUG

PF-00299804

investigational drug by oral route (escalating doses depending on safety) administered until progression

Trial Locations (9)

University of Colorado Hospital, Aurora

Ronald Reagan UCLA Medical Center, Los Angeles

UCLA Hematology/Oncology, Los Angeles

UCLA Oncology Center, Los Angeles

UCLA Hematology Oncology - Santa Monica, Santa Monica

UCLA Santa Monica Hematology/Oncology, Santa Monica

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston

Vereniging het Nederlandse Kanker Instituut, Amsterdam